This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PTX Pernix Therapeutics (PTX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Pernix Therapeutics Stock (NASDAQ:PTX) 30 days 90 days 365 days Advanced Chart Get Pernix Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.03▼$0.2152-Week Range N/AVolume16,105 shsAverage Volume3.04 million shsMarket Capitalization$419 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs primarily for the United States market. It targets underserved therapeutic areas, such as central nervous system (CNS), including pain, neurology, and psychiatry. The company's products comprise Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; Silenor, a non-narcotic, non-scheduled, and non-addictive prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance; and Treximet, a fixed dose combination product indicated for the treatment of acute migraine. Pernix Therapeutics Holdings, Inc. markets and sells its non-core products, including generics through its wholly owned subsidiaries; and markets its non-promoted products through distributors and trade partners. It serves drug wholesalers, specialty pharmacies, retail drug stores, mass merchandisers, and grocery store pharmacies. Pernix Therapeutics Holdings, Inc. was founded in 1996 and is headquartered in Morristown, New Jersey. Read More Receive PTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pernix Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PTX Stock News HeadlinesPANXD PTX Metals Inc.September 27, 2024 | seekingalpha.comBicycle Therapeutics PLC ADR BCYCFebruary 23, 2024 | morningstar.comMIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.July 5 at 2:00 AM | Brownstone Research (Ad)Prescient Therapeutics LtdSeptember 26, 2022 | reuters.comThose who invested in Prescient Therapeutics (ASX:PTX) three years ago are up 307%August 25, 2022 | yahoo.comA Builder From The Ground Up, Doug Drysdale, CEO of Cybin: Meet Our SpeakersApril 6, 2022 | msn.comPernix Therapeutics Holdings Inc (PTX)March 30, 2022 | investing.comMid-Afternoon Market Update: Vivint Solar Dips After Wider-Than-Expected Q3 Loss; Rackspace Shares Spike HigherOctober 26, 2021 | finance.yahoo.comSee More Headlines PTX Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Pernix Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pernix Therapeutics investors own include PIMCO High Income Fund (PHK), Synergy Pharmaceuticals (SGYP), Investors Bancorp (ISBC), Novavax (NVAX), Gevo (GEVO), Amira Nature Foods (ANFI) and Argos Therapeutics (ARGSQ). Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PTX CIK1024126 Webwww.pernixtx.com Phone800-793-2145FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$77.14 million Net Margins-59.70% Pretax MarginN/A Return on EquityN/A Return on Assets-37.01% Debt Debt-to-Equity RatioN/A Current Ratio1.08 Quick Ratio0.92 Sales & Book Value Annual Sales$146.07 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($14.77) per share Price / BookN/AMiscellaneous Outstanding Shares14,510,000Free FloatN/AMarket Cap$419 thousand OptionableOptionable Beta1.20 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:PTX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pernix Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pernix Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.